Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia

Autor: Pasquale Petrone, Andjelija Zivanovic, Sarah Ftouni, Devbarna Sinha, Constantine S. Tam, Maria Joao Silva, Tane Hunter, Gisela Mir Arnau, Paul Yeh, Rishu Agarwal, Ken Doig, Kate Jones, Enid Y.N. Lam, Ravikiran Vedururu, John F. Seymour, Timothy Semple, Mark A. Dawson, Damian Jiang, Stephen Q. Wong, Piers Blombery, Meaghan Wall, Sarah-Jane Dawson, Yih-Chih Chan, Anthony T. Papenfuss, Elise Wallach, David Westerman
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
General Physics and Astronomy
Disease
Ataxia Telangiectasia Mutated Proteins
Somatic evolution in cancer
Circulating Tumor DNA
0302 clinical medicine
Piperidines
immune system diseases
hemic and lymphatic diseases
Receptor
Notch1
Aged
80 and over
Sulfonamides
Multidisciplinary
Hematology
Middle Aged
Baculoviral IAP Repeat-Containing 3 Protein
3. Good health
Leukemia
medicine.anatomical_structure
Treatment Outcome
030220 oncology & carcinogenesis
Disease Progression
Female
RNA Splicing Factors
medicine.medical_specialty
Science
Antineoplastic Agents
Biology
General Biochemistry
Genetics and Molecular Biology
Article
Clonal Evolution
Proto-Oncogene Proteins p21(ras)
03 medical and health sciences
Internal medicine
medicine
Humans
B cell
Aged
Adenine
Cancer
General Chemistry
medicine.disease
Bridged Bicyclo Compounds
Heterocyclic
Phosphoproteins
Minimal residual disease
Leukemia
Lymphocytic
Chronic
B-Cell
Lymphoma
030104 developmental biology
Pyrimidines
Immunology
Myeloid Differentiation Factor 88
Pyrazoles
Tumor Suppressor Protein p53
Zdroj: Nature Communications, Vol 8, Iss 1, Pp 1-7 (2017)
Nature Communications
ISSN: 2041-1723
Popis: Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia (CLL) and the increasing use of these therapies has highlighted limitations of traditional disease monitoring methods. Here we demonstrate that circulating tumour DNA (ctDNA) is readily detectable in patients with CLL. Importantly, ctDNA does not simply mirror the genomic information contained within circulating malignant lymphocytes but instead parallels changes across different disease compartments following treatment with novel therapies. Serial ctDNA analysis allows clonal dynamics to be monitored over time and identifies the emergence of genomic changes associated with Richter's syndrome (RS). In addition to conventional disease monitoring, ctDNA provides a unique opportunity for non-invasive serial analysis of CLL for molecular disease monitoring.
Disease monitoring of chronic lymphocytic leukaemia (CLL) is a challenge. Here, the authors show that serial ctDNA analysis in 32 CLL patients allows monitoring of clonal dynamics over time, and identifies the emergence of genomic changes associated with Richter's syndrome.
Databáze: OpenAIRE
Externí odkaz: